Theresa Cerulli
Psychiatry · North Andover, MANPI 1871604066
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $574,350 of the $724,374 with a category attached, or 79.3%. 21 manufacturers reported payments, led by AbbVie at 46.4% of the total. Reporting peaked in 2023 at $195,445 and has fallen 99.9% since, to $121 in 2025. Among psychiatry clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,141 payments — averaging $634.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$336K
- Supernus Pharmaceuticals, Inc.$217K
- Corium, LLC$53K
- Ironshore Pharmaceuticals Inc.$46K
- Takeda Pharmaceuticals U.S.A., Inc.$20K
- Axsome Therapeutics, Inc.$20K
- plus $33K from 15 others
What the payments were for
- Consulting fees$42,5816%
- Speaking & faculty fees$574,35079%
- Travel & lodging$90,71713%
- Food & beverage$16,7262%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 510 | $335,950 |
| Supernus Pharmaceuticals, Inc. | 295 | $216,549 |
| Corium, LLC | 62 | $52,802 |
| Ironshore Pharmaceuticals Inc. | 85 | $45,501 |
| Takeda Pharmaceuticals U.S.A., Inc. | 34 | $20,438 |
| Axsome Therapeutics, Inc. | 21 | $19,862 |
| Noven Pharmaceuticals, Inc. | 4 | $7,127 |
| Johnson & Johnson | 13 | $7,082 |
| Sunovion Pharmaceuticals Inc. | 29 | $6,646 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 11 | $6,421 |
| Shire North American Group Inc | 37 | $4,721 |
| Neos Therapeutics, LP | 24 | $488 |
| Otsuka America Pharmaceutical, Inc. | 2 | $192 |
| Jazz Pharmaceuticals Inc. | 1 | $125 |
| Collegium Pharmaceutical, Inc. | 1 | $121 |
| Sage Therapeutics, LLC | 1 | $96 |
| Tris Pharma Inc | 2 | $80 |
| Lundbeck LLC | 4 | $79 |
| Merck | 3 | $44 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $34 |
| Rhodes Pharmaceuticals L.p. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$330,157
- QELBREE$86,033
- Azstarys$51,925
- Jornay PM 20mg capsules (Bottle of 100)$32,426
- Auvelity$19,194
- VYVANSE$17,240
- JORNAY PM$11,782
- Xelstrym$7,088
- SPRAVATO$6,772
- TRINTELLIX$6,505
- LATUDA$6,287
- MYDAYIS$679
- XYWAV$125
- Adzenys XR-ODT$123
- Cotempla XR-ODT$123
- REXULTI$102
How this compares
$724,374 in reported general payments places this provider in the 95th percentile of 1,431 psychiatry providers in Massachusetts.
Other psychiatry in North Andover
- Ernesto ZilberbergNorth Andover$141K
- Andrew AldridgeMedford$407K
- Amjad BahnassiWorcester$352K
- Ximena Sanchez-SamperBoston$258K
- Robert AlexanderBelmont$170K
- George PapakostasBoston$170K
- Xiangyang LiMilford$166K
- Maurizio FavaBoston$120K
- Craig SurmanCambridge$111K
- Jessica IsomDorchester$98K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.